McKesson to acquire Precision Medicine Group for $2.25 billion, boosting oncology capabilities
McKesson, a Fortune 500 healthcare wholesaler, announced a $2.25 billion acquisition of privately held Precision Medicine Group.
The deal will fold Precision into McKesson's oncology and multispecialty segment, expanding clinical research, trial execution, and commercialization services.
Founded in 2012, Precision runs five labs in the United States and Europe and, according to its website, helped launch 56% of FDA-approved drugs in 2024.
The acquisition follows McKesson's restructuring last fall that refocused the company on high-margin biopharma and cancer businesses. The transaction still requires regulatory clearance and no timeline has been given.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “McKesson strikes $2.25B deal to snap up Precision Medicine Group”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that